Isaac Stoner

MindImmune is a pre-clinical stage company focused on neuro-inflammation, targeting Alzheimers disease (AD) as initial clinical indication. The companys lead program is an antibody-based therapeutic, aiming to inhibit an innate immune response originating in the periphery which is triggered by AD pathology. The lead program is in late stage pre-clinical development, contemplating IND filing near-term. If successful in clinical development, the companys therapeutic strategy would represent a fundamental breakthrough for the AD field. MindImmune scientists are at the forefront in recognizing the therapeutic opportunities in targeting the immune system to treat brain disease. MindImmune is based in Kingston, RI and is building an affiliation with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island to leverage the rapidly expanding Rhode Island ecosystem of academic neurosciences resources to advance its drug development programs.

The Digital Onboarding adoption platform helps banks and credit unions turn account openers into engaged and profitable relationships. With personalized messages, microsites, and enrollment tools, the platform makes it easy to: ◆ Enroll in direct deposits in seconds ◆ Update default payment methods at multiple merchants at once ◆ Accept pre-approved offers with an eSignature ◆ Enroll in eStatements & Courtesy Pay without logging in ◆ Retrieve account & member numbers online ◆ Opt-in to email & text messages ◆ Adopt additional products ◆ And more! Banks and credit unions can easily track product and service adoption rates and compare their performance to 100+ institutions using the platform. The platform enables institutions to deliver highly personalized communications that are more effective and efficient than traditional welcome kits, mailers, basic emails, and phone calls. The platform was named the Salesforce Accelerate Pitch Competition Winner, FIS Fintech Accelerator MVP Award Winner, Mass Challenge Silver Award Winner, and CreditUnion.com’s Innovation Series Winner (Digital).

Discovering new medicines based on metabolic vulnerabilities in pathological cell populations. Underlying platform uses engineered growth conditions to highlight novel metabolic targets in disease-causing bacteria, lymphocytes, and metastasizing cancer cells. Lead programs in autoimmunity and infectious disease.

Thrive Bioscience’s instruments and software provide automated imaging and analytics of live cells and tissues for research and drug discovery. Thrive instruments automatically build extensive databases of terabytes of time-series images at 100 focal planes of all the cells in all the wells in cell culture plates.

MindImmune is a pre-clinical stage company focused on neuro-inflammation, targeting Alzheimers disease (AD) as initial clinical indication. The companys lead program is an antibody-based therapeutic, aiming to inhibit an innate immune response originating in the periphery which is triggered by AD pathology. The lead program is in late stage pre-clinical development, contemplating IND filing near-term. If successful in clinical development, the companys therapeutic strategy would represent a fundamental breakthrough for the AD field. MindImmune scientists are at the forefront in recognizing the therapeutic opportunities in targeting the immune system to treat brain disease. MindImmune is based in Kingston, RI and is building an affiliation with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island to leverage the rapidly expanding Rhode Island ecosystem of academic neurosciences resources to advance its drug development programs.

The Slater Technology Fund is an evergreen not-for-profit seed fund supporting new venture development in Rhode Island. More than two decades ago, Slater launched a platform for seed-stage investing in Rhode Island; today, the organization remains the most active seed-stage investor in the state. Slater has invested in hundreds of technology ventures in the region, achieving multiple exits while also generating economic impact returns in the form of high-wage jobs.

The Digital Onboarding adoption platform helps banks and credit unions turn account openers into engaged and profitable relationships. With personalized messages, microsites, and enrollment tools, the platform makes it easy to: ◆ Enroll in direct deposits in seconds ◆ Update default payment methods at multiple merchants at once ◆ Accept pre-approved offers with an eSignature ◆ Enroll in eStatements & Courtesy Pay without logging in ◆ Retrieve account & member numbers online ◆ Opt-in to email & text messages ◆ Adopt additional products ◆ And more! Banks and credit unions can easily track product and service adoption rates and compare their performance to 100+ institutions using the platform. The platform enables institutions to deliver highly personalized communications that are more effective and efficient than traditional welcome kits, mailers, basic emails, and phone calls. The platform was named the Salesforce Accelerate Pitch Competition Winner, FIS Fintech Accelerator MVP Award Winner, Mass Challenge Silver Award Winner, and CreditUnion.com’s Innovation Series Winner (Digital).

Discovering new medicines based on metabolic vulnerabilities in pathological cell populations. Underlying platform uses engineered growth conditions to highlight novel metabolic targets in disease-causing bacteria, lymphocytes, and metastasizing cancer cells. Lead programs in autoimmunity and infectious disease.

Discovering new medicines based on metabolic vulnerabilities in pathological cell populations. Underlying platform uses engineered growth conditions to highlight novel metabolic targets in disease-causing bacteria, lymphocytes, and metastasizing cancer cells. Lead programs in autoimmunity and infectious disease.